Dapagliflozin Viatris

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

下载 资料单张 (PIL)
18-01-2024
下载 产品特点 (SPC)
18-01-2024
下载 公众评估报告 (PAR)
04-04-2023

有效成分:

dapagliflozin

可用日期:

Viatris Limited

ATC代码:

A10BK01

INN(国际名称):

dapagliflozin

治疗组:

Drugs used in diabetes

治疗领域:

Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic

疗效迹象:

Type 2 diabetes mellitusDapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance.- in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureDapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.Chronic kidney diseaseDapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease.

授权状态:

Authorised

授权日期:

2023-03-24

资料单张

                                55
B. PACKAGE LEAFLET
56
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DAPAGLIFLOZIN VIATRIS 5 MG FILM-COATED TABLETS
DAPAGLIFLOZIN VIATRIS 10 MG FILM-COATED TABLETS
Dapagliflozin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dapagliflozin Viatris is and what it is used for
2.
What you need to know before you take Dapagliflozin Viatris
3.
How to take Dapagliflozin Viatris
4.
Possible side effects
5.
How to store Dapagliflozin Viatris
6.
Contents of the pack and other information
1.
WHAT DAPAGLIFLOZIN VIATRIS IS AND WHAT IT IS USED FOR
WHAT DAPAGLIFLOZIN VIATRIS IS
Dapagliflozin Viatris contains the active substance dapagliflozin. It
belongs to a group of medicines
called ‘sodium glucose co-transporter-2 (SGLT2) inhibitors’. They
work by blocking the SGLT2
protein in your kidney. By blocking this protein, blood sugar
(glucose), salt (sodium) and water are
removed from your body via the urine.
WHAT DAPAGLIFLOZIN VIATRIS
IS USED FOR
Dapagliflozin Viatris is used to treat:
•
TYPE 2 DIABETES
-
in adults and children aged 10 years and older.
-
if your type 2 diabetes cannot be controlled with diet and exercise.
-
Dapagliflozin Viatris can be used on its own or together with other
medicines to treat
diabetes.
-
It is important to continue to follow the advice on diet and exercise
given to you by your
doctor, pharmacist or nurse.
•
HEART FAILURE
-
in adults (aged 18 years and older) with symptoms due to a weak pump
function of the
heart.
•
CHRONIC KIDNEY DISEASE
-
in adults with reduce
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dapagliflozin Viatris 5 mg film-coated tablets
Dapagliflozin Viatris 10 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dapagliflozin Viatris 5 mg film-coated tablets
Each film-coated tablet contains 5 mg of dapagliflozin.
_ _
_Excipient with known effect _
Each 5 mg tablet contains 24 mg of lactose.
Dapagliflozin Viatris 10 mg film-coated tablets
Each film-coated tablet contains 10 mg of dapagliflozin.
_ _
_Excipient with known effect _
Each 10 mg tablet contains 48 mg of lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Dapagliflozin Viatris 5 mg film-coated tablet
Yellow coloured, round shaped, biconvex film-coated tablet with
diameter of approximetely 7.2 mm.
Debossed with ‘5’ on one side and plain on the other side.
Dapagliflozin Viatris 10 mg film-coated tablet
Yellow coloured, diamond shaped, biconvex with dimensions of
approximately 11 x 8 mm. Debossed
with ‘10’ on one side and plain on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Type 2 diabetes mellitus
Dapagliflozin Viatris is indicated in adults and children aged 10
years and above for the treatment of
insufficiently controlled type 2 diabetes mellitus as an adjunct to
diet and exercise
-
as monotherapy when metformin is considered inappropriate due to
intolerance.
-
in addition to other medicinal products for the treatment of type 2
diabetes.
For study results with respect to combination of therapies, effects on
glycaemic control, cardiovascular
and renal events, and the populations studied, see sections 4.4, 4.5
and 5.1.
3
Heart failure
Dapagliflozin Viatris is indicated in adults for the treatment of
symptomatic chronic heart failure with
reduced ejection fraction.
Chronic kidney disease
Dapagliflozin Viatris is indicated in adults for the treatment of
chronic kidney disease.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Type 2 diabetes mellitus _
The reco
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 18-01-2024
产品特点 产品特点 保加利亚文 18-01-2024
公众评估报告 公众评估报告 保加利亚文 04-04-2023
资料单张 资料单张 西班牙文 18-01-2024
产品特点 产品特点 西班牙文 18-01-2024
公众评估报告 公众评估报告 西班牙文 04-04-2023
资料单张 资料单张 捷克文 18-01-2024
产品特点 产品特点 捷克文 18-01-2024
公众评估报告 公众评估报告 捷克文 04-04-2023
资料单张 资料单张 丹麦文 18-01-2024
产品特点 产品特点 丹麦文 18-01-2024
公众评估报告 公众评估报告 丹麦文 04-04-2023
资料单张 资料单张 德文 18-01-2024
产品特点 产品特点 德文 18-01-2024
公众评估报告 公众评估报告 德文 04-04-2023
资料单张 资料单张 爱沙尼亚文 18-01-2024
产品特点 产品特点 爱沙尼亚文 18-01-2024
公众评估报告 公众评估报告 爱沙尼亚文 04-04-2023
资料单张 资料单张 希腊文 18-01-2024
产品特点 产品特点 希腊文 18-01-2024
公众评估报告 公众评估报告 希腊文 04-04-2023
资料单张 资料单张 法文 18-01-2024
产品特点 产品特点 法文 18-01-2024
公众评估报告 公众评估报告 法文 04-04-2023
资料单张 资料单张 意大利文 18-01-2024
产品特点 产品特点 意大利文 18-01-2024
公众评估报告 公众评估报告 意大利文 04-04-2023
资料单张 资料单张 拉脱维亚文 18-01-2024
产品特点 产品特点 拉脱维亚文 18-01-2024
公众评估报告 公众评估报告 拉脱维亚文 04-04-2023
资料单张 资料单张 立陶宛文 18-01-2024
产品特点 产品特点 立陶宛文 18-01-2024
公众评估报告 公众评估报告 立陶宛文 04-04-2023
资料单张 资料单张 匈牙利文 18-01-2024
产品特点 产品特点 匈牙利文 18-01-2024
公众评估报告 公众评估报告 匈牙利文 04-04-2023
资料单张 资料单张 马耳他文 18-01-2024
产品特点 产品特点 马耳他文 18-01-2024
公众评估报告 公众评估报告 马耳他文 04-04-2023
资料单张 资料单张 荷兰文 18-01-2024
产品特点 产品特点 荷兰文 18-01-2024
公众评估报告 公众评估报告 荷兰文 04-04-2023
资料单张 资料单张 波兰文 18-01-2024
产品特点 产品特点 波兰文 18-01-2024
公众评估报告 公众评估报告 波兰文 04-04-2023
资料单张 资料单张 葡萄牙文 18-01-2024
产品特点 产品特点 葡萄牙文 18-01-2024
公众评估报告 公众评估报告 葡萄牙文 04-04-2023
资料单张 资料单张 罗马尼亚文 18-01-2024
产品特点 产品特点 罗马尼亚文 18-01-2024
公众评估报告 公众评估报告 罗马尼亚文 04-04-2023
资料单张 资料单张 斯洛伐克文 18-01-2024
产品特点 产品特点 斯洛伐克文 18-01-2024
公众评估报告 公众评估报告 斯洛伐克文 04-04-2023
资料单张 资料单张 斯洛文尼亚文 18-01-2024
产品特点 产品特点 斯洛文尼亚文 18-01-2024
公众评估报告 公众评估报告 斯洛文尼亚文 04-04-2023
资料单张 资料单张 芬兰文 18-01-2024
产品特点 产品特点 芬兰文 18-01-2024
公众评估报告 公众评估报告 芬兰文 04-04-2023
资料单张 资料单张 瑞典文 18-01-2024
产品特点 产品特点 瑞典文 18-01-2024
公众评估报告 公众评估报告 瑞典文 04-04-2023
资料单张 资料单张 挪威文 18-01-2024
产品特点 产品特点 挪威文 18-01-2024
资料单张 资料单张 冰岛文 18-01-2024
产品特点 产品特点 冰岛文 18-01-2024
资料单张 资料单张 克罗地亚文 18-01-2024
产品特点 产品特点 克罗地亚文 18-01-2024
公众评估报告 公众评估报告 克罗地亚文 04-04-2023

搜索与此产品相关的警报